文献速递中枢神经肿瘤放疗放疗物理与技术

通过抑制Wee1靶向G2检查点可放射增敏EGFRvIII阳性胶质母细胞瘤细胞

G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells.
PubMed 文献 · Radiat Oncol · 2023-01-29

该研究使用临床相关Wee1抑制剂adavosertib及两对内在表达或不表达EGFRvIII且TP53状态不同的同源胶质母细胞瘤细胞系,并分析EGFRvIII异质性表达的人胶质母细胞瘤样本。结果显示EGFRvIII阳性细胞Wee1表达高于阴性对照,抑制Wee1可消除辐射诱导的G2期阻滞并产生放射增敏,在EGFRvIII阴性与阳性细胞间未见明显差异。作者结论为抑制Wee1是放射增敏EGFRvIII阴性和阳性胶质母细胞瘤细胞的有效靶向策略,可能成为提高放疗反应的新治疗选择。

要点

  • EGFRvIII阳性胶质母细胞瘤细胞中Wee1表达高于EGFRvIII阴性对照细胞。
  • Wee1抑制剂adavosertib可消除辐射诱导的G2期阻滞并放射增敏。
  • 放射增敏在EGFRvIII阴性与阳性胶质母细胞瘤细胞间未见明显差异。

核心结论

  • 作者结论为抑制Wee1是放射增敏EGFRvIII阴性和EGFRvIII阳性胶质母细胞瘤细胞的有效靶向策略,可能成为提高放疗反应的新治疗选择。

研究设计与样本

  • 研究使用临床相关Wee1抑制剂adavosertib及两对内在表达或不表达EGFRvIII且TP53状态不同的同源胶质母细胞瘤细胞系,并分析EGFRvIII异质性表达的人胶质母细胞瘤样本。
  • Wee1表达通过蛋白质印迹和免疫组织化学评估。
  • Wee1抑制联合照射对细胞周期和细胞存活的影响通过流式细胞术和集落形成实验分析。

主要发现

  • 胶质母细胞瘤细胞和患者样本分析显示EGFRvIII阳性细胞Wee1表达高于其EGFRvIII阴性对应细胞。
  • 通过siRNA下调EGFRvIII表达导致Wee1表达强烈下降。
  • 抑制Wee1有效消除辐射诱导的G2期阻滞并引起放射增敏,在EGFRvIII阴性与EGFRvIII阳性胶质母细胞瘤细胞间未见明显差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The gene of the Epidermal growth factor receptor (EGFR) is one of the most frequently altered genes in glioblastoma (GBM), with deletions of exons 2-7 (EGFRvIII) being amongst the most common genomic mutations. EGFRvIII is heterogeneously expressed in GBM. We already showed that EGFRvIII expression has an impact on chemosensitivity, replication stress, and the DNA damage response. Wee1 kinase is a major regulator of the DNA damage induced G2 checkpoint. It is highly expressed in GBM and its overexpression is associated with poor prognosis. Since Wee1 inhibition can lead to radiosensitization of EGFRvIII-negative (EGFRvIII-) GBM cells, we asked, if Wee1 inhibition is sufficient to radiosensitize also EGFRvIII-positive (EGFRvIII+) GBM cells. METHODS: We used the clinically relevant Wee1 inhibitor adavosertib and two pairs of isogenetic GBM cell lines with and without endogenous EGFRvIII expression exhibiting different TP53 status. Moreover, human GBM samples displaying heterogenous EGFRvIII expression were analyzed. Expression of Wee1 was assessed by Western blot and respectively immunohistochemistry. The impact of Wee1 inhibition in combination with irradiation on cell cycle and cell survival was analyzed by flow cytometry and colony formation assay. RESULTS: Analysis of GBM cells and patient samples revealed a higher expression of Wee1 in EGFRvIII+ cells compared to their EGFRvIII- counterparts. Downregulation of EGFRvIII expression by siRNA resulted in a strong decrease in Wee1 expression. Wee1 inhibition efficiently abrogated radiation-induced G2-arrest and caused radiosensitization, without obvious differences between EGFRvIII- and EGFRvIII+ GBM cells. CONCLUSION: We conclude that the inhibition of Wee1 is an effective targeting approach for the radiosensitization of both EGFRvIII- and EGFRvIII+ GBM cells and may therefore represent a promising new therapeutic option to increase response to radiotherapy.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Cetin MH, Rieckmann T, Hoffer K, et al. G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells. Radiat Oncol. 2023. PMID: 36709315. doi:10.1186/s13014-023-02210-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。